3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis

被引:44
作者
Shcherbakova, I [1 ]
Balandrin, MF [1 ]
Fox, J [1 ]
Ghatak, A [1 ]
Heaton, WL [1 ]
Conklin, RL [1 ]
机构
[1] NPS Pharmaceut Inc, Drug Discovery, Salt Lake City, UT 84108 USA
关键词
calcium receptor antagonists; calcilytics; osteoporosis; 3H-quinazolin-4-ones;
D O I
10.1016/j.bmcl.2005.01.078
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Structure-activity relationship studies, focused on identification of the active pharmacophore fragments in a single high-throughput screening calcilytic bit, resulted in the discovery of potent calcium receptor antagonists, substituted 3H-quinazolin-4-ones. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1557 / 1560
页数:4
相关论文
共 16 条
[1]  
BUZAS A, 1959, B SOC CHIM FR, P1889
[2]   Developments in parathyroid hormone and related peptides as bone-formation agents [J].
Fox, J .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (03) :338-344
[3]   Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion [J].
Fox, J ;
Miller, MA ;
Stroup, GB ;
Nemeth, EF ;
Miller, SC .
BONE, 1997, 21 (02) :163-169
[4]   Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats [J].
Gowen, M ;
Stroup, GB ;
Dodds, RA ;
James, IE ;
Votta, BJ ;
Smith, BR ;
Bhatnagar, PK ;
Lago, AM ;
Callahan, JF ;
DelMar, EG ;
Miller, MA ;
Nemeth, EF ;
Fox, J .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1595-1604
[5]   The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides [J].
Gudmundsson, OS ;
Jois, SDS ;
Vander Velde, DG ;
Siahaan, TJ ;
Wang, B ;
Borchardt, RT .
JOURNAL OF PEPTIDE RESEARCH, 1999, 53 (04) :383-392
[6]   N1-arylsulfonyl-N2-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexanes:: A new class of calcilytic agents acting at the calcium-sensing receptor [J].
Kessler, A ;
Faure, H ;
Roussanne, MC ;
Ferry, S ;
Ruat, M ;
Dauban, P ;
Dodd, RH .
CHEMBIOCHEM, 2004, 5 (08) :1131-1136
[7]  
Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
[8]  
Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015
[9]  
Nishioka H, 2000, SYNTHESIS-STUTTGART, P243
[10]  
Papac D.I, 2004, DRUGS FUTURE SA, V29, P331